Edlinger Leo, Berger-Becvar Angelika, Menzl Ingeborg, Hoermann Gregor, Greiner Georg, Grundschober Eva, Bago-Horvath Zsuzsanna, Al-Zoughbi Wael, Hoefler Gerald, Brostjan Christine, Gille Lars, Moriggl Richard, Spittler Andreas, Sexl Veronika, Hoelbl-Kovacic Andrea
Institute of Pharmacology and Toxicology, Department of Biomedical Sciences, University of Veterinary Medicine Vienna, Vienna, Austria.
Department of Chemical and Physical Sciences, University of Toronto Mississauga, Mississauga, ON, Canada.
Br J Haematol. 2017 Oct;179(2):229-241. doi: 10.1111/bjh.14833. Epub 2017 Jul 14.
The p21-activated kinases (PAKs) are key nodes in oncogenic signalling pathways controlling growth, survival, and motility of cancer cells. Their activity is increased in many human cancers and is associated with poor prognosis. To date, PAK deregulation has mainly been studied in solid tumours, where PAK1 and PAK4 are the main isoforms deregulated. We show that PAK1 and PAK2 are the critical isoforms in a BCR/ABL1 haematopoietic malignancy. In suspension, leukaemic cells deficient for PAK1 and PAK2 undergo apoptosis, while the loss of either protein is well tolerated. Transfer of medium conditioned by shPAK2- but not shPAK1-expressing leukaemic cells interferes with endothelial cell growth. We found that leukaemic cells produce exosomes containing PAK2. Transfer of isolated exosomes supports endothelial cell proliferation. In parallel, we found that leukaemic cells explicitly require PAK2 to grow towards an extracellular matrix. PAK2-deficient cells fail to form colonies in methylcellulose and to induce lymphomas in vivo. PAK2 might therefore be the critical isoform in leukaemic cells by controlling tumour growth in a dual manner: vascularization via exosome-mediated transfer to endothelial cells and remodelling of the extracellular matrix. This finding suggests that the PAK2 isoform represents a promising target for the treatment of haematological diseases.
p21激活激酶(PAKs)是致癌信号通路中的关键节点,控制癌细胞的生长、存活和迁移。它们的活性在许多人类癌症中升高,并与不良预后相关。迄今为止,PAK失调主要在实体瘤中进行研究,其中PAK1和PAK4是主要的失调亚型。我们发现PAK1和PAK2是BCR/ABL1造血恶性肿瘤中的关键亚型。在悬浮培养中,缺乏PAK1和PAK2的白血病细胞会发生凋亡,而单独缺失任何一种蛋白都能被很好地耐受。由表达shPAK2而非shPAK1的白血病细胞条件培养基的转移会干扰内皮细胞生长。我们发现白血病细胞产生含有PAK2的外泌体。分离的外泌体的转移支持内皮细胞增殖。同时,我们发现白血病细胞明确需要PAK2才能向细胞外基质生长。缺乏PAK2的细胞在甲基纤维素中无法形成集落,在体内也无法诱导淋巴瘤。因此,PAK2可能是白血病细胞中的关键亚型,通过以双重方式控制肿瘤生长:通过外泌体介导转移至内皮细胞实现血管生成以及细胞外基质重塑。这一发现表明PAK2亚型是治疗血液系统疾病的一个有前景的靶点。